Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2079 - Efficacy and Safety of Trabectedin in an Elderly Patient Subgroup (≥65 years) with Advanced Leiomyosarcoma (LMS) or Liposarcoma (LPS) from the Expanded Access Program (EAP)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Geriatric Oncology;  Soft Tissue Sarcomas


Robin Jones


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


R.L. Jones1, R. Maki2, S. Patel3, G. Wang4, C.R. Shin5, R. Knoblauch6, G.D.S. Demetri7

Author affiliations

  • 1 Sarcoma Unit, Royal Marsden Hospital/Institute of Cancer Research, SM2 5NG - London/GB
  • 2 Medical Oncology And Hematology, Monter Cancer Center, Lake Success/US
  • 3 Oncology, The University of Texas, MD Anderson Cancer Center, Houston/US
  • 4 Biostats, Janssen Research & Development, LLC, Spring House/US
  • 5 Med Group Oncology, Janssen Scientific Affairs, LLC, Horsham/US
  • 6 Clinical Oncology, Janssen Research & Development, LLC, 8869 - Raritan/US
  • 7 Center For Sarcoma And Bone Oncology, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston/US


Abstract 2079


Elderly patients (pts) (≥65 yrs) with soft tissue sarcoma may have limited treatment options due to increased comorbidities and toxicities from available therapeutic agents. Previous retrospective analyses have suggested that trabectedin (T) has similar safety and efficacy outcomes irrespective of pt age.


In this multicenter, open-label study, pts received IV T (1.5 mg/m2) every 3 wks. We retrospectively analyzed the efficacy and safety of T in pts ≥65 yrs treated from 2005-2010 on this EAP.


Mean age was 71 and 49 in the ≥65 (n = 350) and 12 mo) was 26 (7.4%) and 107 (7.4%) in the ≥65 and


The efficacy and safety profile of T in pts ≥65 was similar to that observed in pts

Clinical trial identification


Legal entity responsible for the study

Janssen Research & Development, LLC


Janssen Research & Development, LLC


R.L. Jones: Consultant for: Adaptimmune, Blueprint, Eisai, Epizyme, Daichii, Deciphera, Janssen Scientific Affairs, LLC, Immunedesign, Lilly, Merck, Pharmamar. R. Maki: Consulting or advisory role: SARC, ASCO, AADX, ARCUS, Bayer, GSAI, GEM, Novartis, GSK, Immune Design, Janssen, Kyropharm, Lilly Tracon and Presage. Research funding & travel, accommodations, expenses: Tracon, Immune Design, Lilly and SARC. S. Patel: Consultant to: Janssen, Eisai, Novartis, CytRx, Epizyme, Bayer, Eli Lilly. Grants for clinical trial from: Janssen, Eisai, Morphotek. G. Wang, C.R. Shin, R. Knoblauch: Employment with Janssen and Johnson & Johnson stock ownership. G.D.S. Demetri: Consulting: Novartis, Janssen, PharmaMar, Daiichi-Sankyo, Adaptimmune, Eisai Patent licensed to Novartis from Dana-Farber with royalty paid to Dana-Farber Research support to Dana-Farber: Novartis, Janssen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.